Gastric cancer: a comprehensive review of current and future treatment strategies
RE Sexton, MN Al Hallak, M Diab, AS Azmi - Cancer and Metastasis …, 2020 - Springer
Gastric cancer remains a major unmet clinical problem with over 1 million new cases
worldwide. It is the fourth most commonly occurring cancer in men and the seventh most …
worldwide. It is the fourth most commonly occurring cancer in men and the seventh most …
Spatial transcriptomics and proteomics technologies for deconvoluting the tumor microenvironment
N Wang, X Li, R Wang, Z Ding - Biotechnology journal, 2021 - Wiley Online Library
The tumor microenvironment (TME) harbors heterogeneous contents and plays critical roles
in tumorigenesis, metastasis, and drug resistance. Therefore, the deconvolution of the TME …
in tumorigenesis, metastasis, and drug resistance. Therefore, the deconvolution of the TME …
Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives
E Abdi, S Latifi‐Navid, S Zahri, A Yazdanbod… - Cancer …, 2019 - Wiley Online Library
Recent decades have seen an alarming increase in the incidence of cardia gastric
adenocarcinoma (CGA) while noncardia gastric adenocarcinoma (NCGA) has decreased. In …
adenocarcinoma (CGA) while noncardia gastric adenocarcinoma (NCGA) has decreased. In …
[HTML][HTML] Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives
A Pellino, E Riello, F Nappo, S Brignola… - World journal of …, 2019 - ncbi.nlm.nih.gov
Gastric cancer (GC) represents a leading cause of cancer related morbidity and mortality
worldwide accounting for more than 1 million of newly diagnosed cases and thousands of …
worldwide accounting for more than 1 million of newly diagnosed cases and thousands of …
Dissection of gastric cancer heterogeneity for precision oncology
SWT Ho, P Tan - Cancer science, 2019 - Wiley Online Library
Gastric cancer (GC) remains the fifth most prevalent cancer worldwide and the third leading
cause of global cancer mortality. Comprehensive‐omic studies have unveiled a …
cause of global cancer mortality. Comprehensive‐omic studies have unveiled a …
[HTML][HTML] Natural killer cell and stroma abundance are independently prognostic and predict gastric cancer chemotherapy benefit
BACKGROUND Specific features of the tumor microenvironment (TME) may provide useful
prognostic information. We conducted a systematic investigation of the cellular composition …
prognostic information. We conducted a systematic investigation of the cellular composition …
Biology-guided deep learning predicts prognosis and cancer immunotherapy response
Substantial progress has been made in using deep learning for cancer detection and
diagnosis in medical images. Yet, there is limited success on prediction of treatment …
diagnosis in medical images. Yet, there is limited success on prediction of treatment …
Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study
Background The tumour stroma microenvironment plays an important part in disease
progression and its composition can influence treatment response and outcomes …
progression and its composition can influence treatment response and outcomes …
Clinical molecular subtyping reveals intrinsic mesenchymal reprogramming in gastric cancer cells
E Jang, MK Shin, H Kim, JY Lim, JE Lee… - … & Molecular Medicine, 2023 - nature.com
The mesenchymal cancer phenotype is known to be clinically related to treatment resistance
and a poor prognosis. We identified gene signature-based molecular subtypes of gastric …
and a poor prognosis. We identified gene signature-based molecular subtypes of gastric …
Phase Ib study of navicixizumab plus paclitaxel in patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer
S Fu, BR Corr, K Culm-Merdek, C Mockbee… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE This phase Ib study evaluated the safety and efficacy of paclitaxel plus
navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth factor …
navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth factor …